K
2.10
-0.04 (-1.87%)
Penutupan Terdahulu | 2.14 |
Buka | 2.11 |
Jumlah Dagangan | 152,709 |
Purata Dagangan (3B) | 301,712 |
Modal Pasaran | 92,488,408 |
Harga / Buku (P/B) | 0.300 |
Julat 52 Minggu | |
Tarikh Pendapatan | 12 May 2025 - 19 May 2025 |
EPS Cair (TTM) | -3.33 |
Jumlah Hutang/Ekuiti (D/E MRQ) | 3.09% |
Nisbah Semasa (MRQ) | 8.61 |
Aliran Tunai Operasi (OCF TTM) | -114.25 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -69.56 M |
Pulangan Atas Aset (ROA TTM) | -46.93% |
Pulangan Atas Ekuiti (ROE TTM) | -80.74% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Menurun | Menurun |
Biotechnology (Global) | Menurun | Menurun | |
Stok | Kyverna Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
1.0
Konsensus Penganalisis | 3.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 0.5 |
Purata Bergerak Teknikal | 0.0 |
Osilator Teknikal | 0.5 |
Purata | 1.00 |
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases. |
|
Sektor | Healthcare |
Industri | Biotechnology |
% Dimiliki oleh Orang Dalam | 2.26% |
% Dimiliki oleh Institusi | 85.04% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Mbb Public Markets I Llc | 31 Dec 2024 | 614,477 |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 20.00 (Morgan Stanley, 852.38%) | Beli |
Median | 12.50 (495.24%) | |
Rendah | 5.00 (HC Wainwright & Co., 138.10%) | Beli |
Purata | 12.50 (495.24%) | |
Jumlah | 2 Beli | |
Harga Purata @ Panggilan | 2.03 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
HC Wainwright & Co. | 27 May 2025 | 5.00 (138.10%) | Beli | 2.07 |
03 Apr 2025 | 4.00 (90.48%) | Pegang | 1.97 | |
Morgan Stanley | 01 Apr 2025 | 20.00 (852.38%) | Beli | 1.98 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
28 May 2025 | Pengumuman | Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference |
13 May 2025 | Pengumuman | Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results |
27 Mar 2025 | Pengumuman | Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results |
03 Mar 2025 | Pengumuman | Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |